Mexedia: Green Light for a €20 Million Capital Increase Reserved for Likan AG
Meeting on October 28, 2026 in second call in Rome, Mexedia shareholders approved an issuance potentially reaching 20 million euros, including share premium, at €1.00 per share. Up to 20,000,000 new shares could thus be created, while the capital comprises 8,353,129 ordinary shares.
An issuance in several tranches without preferential subscription rights
The ordinary and extraordinary general meeting, held at the company's registered office, approved all resolutions on the agenda. Shareholders present or represented held 3,192,305 ordinary shares, representing 38.22% of the capital.
The capital increase approved is paid, divisible and executable in several tranches, with the suppression of preferential subscription rights under Article 2441, paragraph 5, of the Italian civil code. It is reserved for Likan AG, a Swiss company headquartered in Zug.
Each new share, with no par value and having the same characteristics as shares in circulation, is divided into €0.02 of capital and €0.98 of share premium. The issuance must take place within twelve months from the signing of final agreements with the investor, and no later than December 31, 2027.
Shareholders voted after examination of the board of directors' report and the opinion on the appropriateness of the price rendered by the supervisory body (Collegio Sindacale). They approved the corresponding amendment to Article 6 of the bylaws.
The board mandated to sign agreements and launch an initial €1 million tranche
Shareholders entrusted the board of directors, and through it the Chief Executive Officer Paolo Bona, with the powers necessary to execute the operation. He may sign final agreements with Likan AG, under conditions consistent with those in the board's report, after prior approval of the text by the board acting collectively.
These powers also cover verification of conditions specific to each tranche, receipt of subscriptions, issuance of new shares and request for their admission to trading on Euronext Growth Paris.
An initial tranche of €1,000,000 is planned at the signing of final agreements; the company will inform the market of this signing and the execution of each tranche.
In the ordinary portion, the meeting confirmed co-opted director Sara Di Mario, appointed on July 2, 2026 and serving until the meeting approving the accounts for fiscal year 2026. The bylaws were also adapted to Legislative Decree No. 47 of March 27, 2026, concerning the replacement of directors as well as the convening and conduct of meetings of corporate bodies.
Execution subject to final agreements and their conditions
According to the company, the execution of each tranche remains subject to the signing of final agreements with the investor and the conditions that will be included therein. Mexedia indicates that there is no guarantee that the announced results will be achieved, in particular regarding the completion and timing of the operation.
If the capital increase is not fully subscribed within the set period, the capital will be increased only by the amount of subscriptions received. The operation, reserved for Likan AG, does not give rise to any public offering; the board's report and the supervisory body's opinion have been available on the company's website since October 10, 2026.
